Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Combination therapies with daclatasvir and asunaprevir on NS3-D168 mutated HCV in human hepatocyte chimeric mice.

Antiviral therapy - 1 Jan 2016

Kan Hiromi, Hiraga Nobuhiko, Imamura Michio, Hayes C Nelson, Uchida Takuro, Miyaki Eisuke, Tsuge Masataka, Abe Hiromi, Aikata Hiroshi, Miki Daiki, Ochi Hidenori, Ishida Yuji, Tateno Chise, Chayama Kazuaki

Abstract excerpt

BACKGROUND: Although the frequency of emergent drug-resistant strains of HCV in patients who failed to respond to simeprevir plus pegylated interferon (PEG-IFN) and ribavirin (RBV) decreased after cessation of the treatment, it is not clear whether or not the NS3-D168 variants affect the outcome of NS5A and NS3 inhibitor combination therapy. In this study, we investigated the relationship between the effect of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carbamates
Share to Chimera

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Hepatocytes

Share to Imidazoles

Share to Isoquinolines

Share to Pyrrolidines

Share to Sulfonamides

Share to Valine

Source

Identifiers

PMID: 26562322
DOI: 10.3851/IMP3009

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

Combination therapies with daclatasvir and asunaprevir on NS3-D168 mutated HCV in human hepatocyte chimeric mice.PMID 26562322Read ↗

Combination therapies with NS5A, NS3 and NS5B inhibitors on different genotypes of hepatitis C virus in human hepatocyte chimeric mice.Semantic proximity Read ↗

HA1077 displays synergistic activity with daclatasvir against hepatitis C virus and suppresses the emergence of NS5A resistance-associated substitutions in mice.Semantic proximity Read ↗

Evolution and persistence of resistance-associated substitutions of hepatitis C virus after direct-acting antiviral treatment failures.Semantic proximity Read ↗

Novel drug resistance-associated substitutions against pibrentasvir emerged in genotype 1b hepatitis C virus-infected human hepatocyte transplanted mice.Semantic proximity Read ↗

Rapid emergence of telaprevir resistant hepatitis C virus strain from wildtype clone in vivo.Semantic proximity Read ↗

Targeting a host-cell entry factor barricades antiviral-resistant HCV variants from on-therapy breakthrough in human-liver mice.Semantic proximity Read ↗

Baseline quasispecies selection and novel mutations contribute to emerging resistance-associated substitutions in hepatitis C virus after direct-acting antiviral treatment.Semantic proximity Read ↗

Limitations of daclatasvir/asunaprevir plus beclabuvir treatment in cases of NS5A inhibitor treatment failure.Semantic proximity Read ↗

Intrinsic Viral Factors Are the Dominant Determinants of the Hepatitis C Virus Response to Interferon Alpha Treatment in Chimeric Mice.Semantic proximity Read ↗

Effect of D168V mutation in NS3/4A HCV protease on susceptibilities of faldaprevir and danoprevir.Semantic proximity Read ↗

Lethal Mutagenesis of Hepatitis C Virus Induced by Favipiravir.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.